Follow The Filings

SION Sionna Therapeutics Inc.

Health Care, filed as SIONNA THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.4%
  • $141M
  • 1 exit

In 2026 Q2 Polen Capital Management sold out of Sionna Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 0.4% (Andreas Halvorsen, Viking Global Investors). Not free-float ownership.

  1. Andreas Halvorsen 0.40%

Who owns SION

Sorted by value, long equity only, as of 2026 Q2.

History
Andreas Halvorsen, Viking Global Investors 0.40% Hold 3,195,181 $141M History
Polen Capital Management exited 2026 Q2 Last 2026 Q1 0.01% Exit −0.01% 26,775 $1.1M History

1 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by SION's executives, directors and 10% owners in the last 12 months, from their Form 4s

All SION insider trades
  • None no insider bought on the open market
  • $53.3M sold by 2 insiders outside a trading plan
  • $113M sold by 3 insiders under 10b5-1 plans
  1. Ra Capital Management, L.P. Director, +5 joint filers
    Sale
    $21.8M 3,448,811 shares at $6.33 50% of stake
    Traded Sep 17 Filed Sep 21
    ↗
  2. Peter A. Thompson Director
    Planned sale
    $3.9M 85,918 shares at $44.86 3.4% of stake
    Traded Jul 7 Filed Jul 9
    ↗
  3. Jennifer Fitzpatrick Chief Legal Officer
    Planned sale
    $447K 10,250 shares at $43.60 100% of stake
    Traded Jul 6 Filed Jul 7
    ↗
  4. Peter A. Thompson Director
    Planned sale
    $5.3M 115,844 shares at $45.50 4.3% of stake
    Traded Jun 30 Filed Jul 2
    ↗
  5. Peter A. Thompson Director
    Planned sale
    $4,493 101 shares at $44.49 <0.1% of stake
    Traded May 27 Filed May 29
    ↗
  6. Peter A. Thompson Director
    Planned sale
    $13.4M 292,952 shares at $45.62 9.9% of stake
    Traded May 7–11 Filed May 11
    ↗
  7. Peter A. Thompson Director
    Planned sale
    $2.5M 55,345 shares at $44.67 1.8% of stake
    Traded Apr 17–18 Filed Apr 21
    ↗
  8. Peter A. Thompson Director
    Planned sale
    $22.9M 510,583 shares at $44.94 15% of stake
    Traded Apr 14–16 Filed Apr 16
    ↗
  9. Jennifer Fitzpatrick Chief Legal Officer
    Planned sale
    $347K 10,250 shares at $33.86 100% of stake
    Traded Mar 5 Filed Mar 6
    ↗

Also filed in the last 12 months, not counted as buying or selling: 8 stock grants and 3 option exercises.

SEC filings

Recent issuer filings from EDGAR, 13 shown.

Filed Form Detail Links
SCHEDULE 13D/A — Filing Doc
8-K 2.05,5.02,8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D/A — Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2025
Net income -$75.27M

Balance sheet

Metric FY2025
Total current assets $241.42M
Total non-current assets * $84.53M
Total assets $325.95M
Total current liabilities $11.71M
Total non-current liabilities * $7.41M
Total equity $306.83M

Cash flow

Metric FY2025
Cash from operations -$66.3M
Cash from investing -$118.75M
Cash from financing $205.71M
Net change in cash $20.66M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.